Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy
Stopped early · Phase 1/Phase 2
Conditions studied: Breakthrough Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
In brief
RATIONALE: Antiemetic drugs, such as fosaprepitant dimeglumine, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. PURPOSE: This clinical trial is studying the side effects of fosaprepitant dimeglumine and to see how well it works in treating patients with nausea and vomiting caused by chemotherapy.
Key facts
- Study ID
- NCT01031953
- Run by
- OHSU Knight Cancer Institute
- People needed
- 34
- Starts
- 2008-08-01
- Expected to finish
- 2013-02-01
- Last updated by the study team
- 2017-05-09
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Knight Cancer Institute at Oregon Health and Science University — Portland, Oregon, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.